BASF completes €270m sale of custom synthesis business to Siegfried Holding

Published: 1-Oct-2015
Finance Digital

Deal includes parts of BASF's active pharmaceutical ingredients business


BASF has sold its pharmaceutical custom synthesis business and parts of its active pharmaceutical ingredients (APIs) business to Siegfried Holding for €270m.

The sale was first announced in May and the relevant merger control approvals have now been granted.

From today, Siegfried Holding has taken over the operational management of the businesses and around 850 people have transferred to Siegfried.

The APIs sold to Siegfried include ephedrine, pseudoephedrine and caffeine.

Ibuprofen, omega-3 fatty acids and polyethylenglycol (PEG) will remain a key part of BASF’s portfolio.

  • Companies:
  • BASF Personal Care and Nutrition GmbH
See more

You may also like

Ingredients

Five key takeaways from LogiChem EU 2019

Read more
Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. Gerresheimer acquires Bormioli Pharma Group through Blitz LuxCo Sarl merger Gerresheimer and Bormioli Pharma will merge to provide the biotech and pharmaceutical industries with primary packaging solutions, dosing systems, closure solutions and accessories

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Ingredients

Five key takeaways from LogiChem EU 2019

Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community
Manufacturing

BASF selects Emerson to enhance flexibility and production at German chemical plant

Emerson automation to improve operational efficiency and enhance cybersecurity for world’s largest chemical manufacturer
Manufacturing

BASF invests in carbon recycling company LanzaTech

The patented biotechnological procedure cuts carbon dioxide emissions by turning carbon monoxide and hydrogen into ethanol
Ingredients

Colorcon to purchase BASF’s Kollicoat IR coating system product line

The two firms will also further their cooperation to offer superior functional coatings for pharmaceutical tablets
Design & Build

Siegfried acquires three BASF sites

Acquisition represents the final step in Siegfried’s targeted 5-year procurement policy
Ingredients

BASF to sell custom synthesis and parts of pharma API business to Siegfried Holding

Ibuprofen, omega-3 fatty acids and polyethylenglycol will remain a key part of BASF’s portfolio
Finance

BASF to cut 260 jobs in Nutrition & Health division by 2015

Aims to strengthen profitability of its Performance Products segment
Subscribe now